论文部分内容阅读
作者用2.5μg酵母重组乙型肝炎疫苗给54名17～19岁男性新兵分别接种3次(第0、1和6个月),与过去在同样条件下接种5和10μg重组疫苗组的结果进行比较。首针后第1、3、6和7个月用Abbott放射免疫试剂盒测定表面抗体(抗-HBs)和核心抗体(抗-HBc)。用稀释的WHO参考制剂的校准曲线校准抗-HBs国际单位含量。第1个月三组血清阳转率无统计学差异。加强接种时,5和10μg组已全部阳转,但2.5μg组54人中有4人未阳转。到第7个月,各组血清阳转率均达100%,但2.5μg组仍有3人(6%)抗-HBs未达到保护水平(10IU/l),另有8人(15%)抗体效价低于100IU/l。经非
The authors vaccinated 54 young men aged 17 to 19 three times (0, 1, and 6 months) with a 2.5 μg yeast recombinant hepatitis B vaccine, respectively, as compared to the results obtained with the 5 and 10 μg recombinant vaccines previously vaccinated under the same conditions Compare Surface antibodies (anti-HBs) and core antibodies (anti-HBc) were assayed at 1, 3, 6 and 7 months after the first injection using the Abbott radioimmunoassay kit. Anti-HBs International Units were calibrated with the calibration curve of the diluted WHO reference formulation. The first three months of seroconversion rate was no significant difference. At the time of vaccination, all animals in the 5 and 10 μg groups were fully positive, but 4 out of 54 in the 2.5 μg group did not. By the 7th month, seroconversion rates were 100% in each group, but 3 (6%) still did not reach the level of protection (10IU / l) in 2.5μg group, and 8 (15% Antibody titers are below 100 IU / l. By non